Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Deborah Schofield, Joshua Kraindler, Owen Tan, Rupendra Shrestha, Diana Jelovic, Sarah West, John Grigg, Robyn V. Jamieson
Abstract
Authors
Institutions
No ROR-resolved institution is linked to this work yet.
Provenance
crossref
Confidence 100%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
doaj
Confidence 92%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Gene therapy for retinal dystrophy
10.1038/s41591-019-0346-1 · 2019
Unresolved referenced work
Kept as external metadata until matched
A comparison of the causes of blindness certifications in England and Wales in working age adults (16–64 years), 1999–2000 with 2009–2010
10.1136/bmjopen-2013-004015 · 2014
Worldwide carrier frequency and genetic prevalence of autosomal recessive inherited retinal diseases
10.1073/pnas.1913179117 · 2020
Clinical and genetic characteristics of 251 consecutive patients with macular and cone/cone-rod dystrophy
10.1038/s41598-018-22096-0 · 2018
Nonsyndromic retinitis pigmentosa overview. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle
2000
The economic impact of blindness in Europe
10.1080/09286586.2017.1281426 · 2017
Navigating the current landscape of clinical genetic testing for inherited retinal dystrophies
10.1038/gim.2015.15 · 2015
Cost-effectiveness of voretigene neparvovec-rzyl vs standard care for RPE65-mediated inherited retinal disease
10.1001/jamaophthalmol.2019.2512 · 2019
Inherited retinal disorders: using evidence as a driver for implementation
10.1159/000500574 · 2019
Progress in treating inherited retinal diseases: early subretinal gene therapy clinical trials and candidates for future initiatives
10.1016/j.preteyeres.2019.100827 · 2020
Safety and vision outcomes of subretinal gene therapy targeting cone photoreceptors in achromatopsia: a nonrandomized controlled trial
10.1001/jamaophthalmol.2020.1032 · 2020
Beneficial effects on vision in patients undergoing retinal gene therapy for choroideremia
10.1038/s41591-018-0185-5 · 2018
Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR
10.1038/s41591-020-0763-1 · 2020
Unresolved referenced work
2017
Health outcomes in economic evaluation: the QALY and utilities
10.1093/bmb/ldq033 · 2010
Cost utility of voretigene neparvovec for biallelic RPE65-mediated inherited retinal disease
10.1016/j.jval.2018.09.2841 · 2019
Cost effectiveness of voretigene neparvovec for RPE65-mediated inherited retinal degeneration in Germany
10.1167/tvst.9.9.17 · 2020
An economic evaluation of voretigene neparvovec for the treatment of biallelic RPE65-mediated inherited retinal dystrophies in the UK
10.1007/s12325-020-01243-y · 2020
PSS11 costs and quality of life of RPE65-mediated inherited retinal dystrophies in Portugal
10.1016/j.jval.2020.08.1973 · 2020
Methodological challenges in the economic evaluation of a gene therapy for RPE65-mediated inherited retinal disease: the value of vision
10.1007/s40273-021-01003-y · 2021
Potential lifetime quality of life benefits of choroideremia gene therapy: projections from a clinically informed decision model
10.1038/s41433-019-0492-1 · 2019
Eye health and quality of life: an umbrella review protocol
10.1136/bmjopen-2020-037648 · 2020
Utility of the National Eye Institute VFQ-25 questionnaire in a heterogeneous group of multiple sclerosis patients
10.1016/j.ajo.2006.04.051 · 2006
Development of a preference-based index from the National Eye Institute Visual Function Questionnaire-25
10.1001/jamaophthalmol.2013.7639 · 2014
Estimating quality-adjusted life years from patient-reported visual functioning
10.1038/eye.2012.137 · 2012
Predicting EQ-5D utility scores from the 25-item National Eye Institute Vision Function Questionnaire (NEI-VFQ 25) in patients with age-related macular degeneration
10.1007/s11136-009-9499-6 · 2009
Validity and reliability of the Assessment of Quality of Life (AQoL)-8D multi-attribute utility instrument
10.1007/s40271-013-0036-x · 2014
Development of the 25-item National Eye Institute Visual Function Questionnaire
10.1001/archopht.119.7.1050 · 2001
Psychometric properties of the National Eye Institute Visual Function Questionnaire (NEI-VFQ). NEI-VFQ Field Test Investigators
10.1001/archopht.116.11.1496 · 1998
Quantitative analyses of factors related to anxiety and depression in patients with retinitis pigmentosa
10.1371/journal.pone.0195983 · 2018
Unresolved referenced work
2016
Value of whole exome sequencing for syndromic retinal dystrophy diagnosis in young patients
10.1111/ceo.12391 · 2015
Clinically focused molecular investigation of 1000 consecutive families with inherited retinal disease
10.1016/j.ophtha.2017.04.008 · 2017
Clinical progress in inherited retinal degenerations: gene therapy clinical trials and advances in genetic sequencing
10.1097/iae.0000000000001341 · 2017
Clinical utility of genetic testing in 201 preschool children with inherited eye disorders
10.1038/s41436-019-0722-8 · 2020
Important considerations in modeling the cost-effectiveness for the first Food and Drug Administration–approved gene therapy and implications for future one-time therapies
10.1016/j.jval.2018.12.013 · 2019
Estimation of impact of RPE65-mediated inherited retinal disease on quality of life and the potential benefits of gene therapy
10.1136/bjophthalmol-2018-313089 · 2019
A comparison of the sensitivity of EQ-5D, SF-6D and TTO utility values to changes in vision and perceived visual function in patients with primary open-angle glaucoma
10.1186/1471-2415-12-43 · 2012
Psychosocial impacts of Mendelian eye conditions: a systematic literature review
10.1016/j.survophthal.2020.02.002 · 2020
No additional external references are available.